Oncology · Mental HealthTrial Updateclinicalmid-term

Psilocybin-Assisted Psychotherapy Trial for Cancer Survivors Launched

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/25/2026, 6:30:35 PM

Assessment confidence: 79% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The launch of this clinical trial for psilocybin-assisted psychotherapy represents a significant development in the intersection of oncology and mental health. A successful outcome could reshape treatment protocols and create new partnerships, thereby altering competitive dynamics in the market. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 24 ranked evidence items (18 high-relevance).

Strategic Assessment

If successful, this could lead to new treatment protocols and partnerships in the oncology and mental health sectors, influencing competitive dynamics. The strongest clinical anchor is TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors (ClinicalTrials.gov), entity match (m d anderson cancer center). In Oncology · Mental Health, 4 regulatory and 4 competitive items passed relevance filtering for M.D.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer). Secondary pressure from Merck's Sacituzumab Tirumotecan Trial Targets High-Risk Breast Cancer. This trial could position psilocybin as a novel treatment option in the oncology mental health space, potentially impacting existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. The trial's outcomes may prompt regulatory reviews and approvals, influencing how psilocybin is positioned within treatment guidelines for cancer survivors.

Key Risks

Elevated medium regulatory exposure for M.D. Anderson Cancer Center could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If psilocybin is validated as a treatment option, it could capture market share from existing therapies, leading to potential revenue growth for companies involved in this space.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Oncology · Breast Cancer · Trial Update · This trial could position Merck favorably against competitors in the breast cancer treatment landscape, particularly in the triple-negative and HR-low positive/HER2-negative segments.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent regulatory actions or partnerships that may arise from the findings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Pioneering AI health innovations regulatory sandbox launched
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
ClinicalTrials.govhigh relevance
Entity match (m d anderson cancer center)
FDA document
View source
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
ClinicalTrials.govhigh relevance
Entity match (m d anderson cancer center)
FDA document
View source
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govhigh relevance
Entity match (m d anderson cancer center)
FDA document
View source
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Merck's Sacituzumab Tirumotecan Trial Targets High-Risk Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Cadonilimab Targets PD-1/PD-L1 Blockade-Refractory MSI-H/dMMR Colorectal Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Epcoritamab Shows Promise in High-risk Burkitt Lymphoma with DA-EPOCH-R in Phase II Trial
Humanexa Signalsmedium relevance
Moderate corpus alignment

Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

M.D. Anderson Cancer Center

Commercial impact

medium

If psilocybin is validated as a treatment option, it could capture market share from existing therapies, leading to potential revenue growth for companies involved in this space.

Regulatory impact

medium

The trial's outcomes may prompt regulatory reviews and approvals, influencing how psilocybin is positioned within treatment guidelines for cancer survivors.

What to watch

Monitor trial results and any subsequent regulatory actions or partnerships that may arise from the findings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.